TheEdgeResearch
Home / Stocks / GLPG

Galapagos N.V. (GLPG)

NASDAQ Healthcare Biotechnology
$27.98 ▲ +1.71%
Market Cap
$1.84B
Sector
Healthcare
Industry
Biotechnology
Beta
0.30
52-Wk Range
—
CEO
Henry O. Gosebruch
Country
BE
Currency
USD

Galapagos N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mechelen, BE. The stock last traded at $27.98, up 1.71% on the session, giving a market capitalisation of $1.84B. On trailing twelve-month figures it carries a trailing P/E of 2.82, a net margin of 60.2%. Its beta of 0.30 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
2.82
Price / Sales
1.70
Price / Book
0.55
EV / EBITDA
6.20
Gross margin
97.4%
Operating margin
40.7%
Net margin
60.2%
Return on equity
—
Debt / equity
0.00
Current ratio
30.48
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
452
IPO date
2012-02-27
Headquarters
Mechelen, BE
About Galapagos N.V.

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Comparable companies

Galapagos N.V. is most often compared with the following Healthcare names:

ARGXASMBCTMXKYNBNXTCRARESPRO
More research on GLPG
GLPG technical analysis GLPG TheEdge Score Compare against peers
Open full interactive analysis & DCF →